D
Debra Van Egeren
Researcher at Harvard University
Publications - 12
Citations - 235
Debra Van Egeren is an academic researcher from Harvard University. The author has contributed to research in topics: Population & Public health. The author has an hindex of 4, co-authored 12 publications receiving 72 citations. Previous affiliations of Debra Van Egeren include Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms
Debra Van Egeren,Debra Van Egeren,Javier Escabi,Maximilian Nguyen,Shichen Liu,Christopher R. Reilly,Sachin Patel,Baransel Kamaz,Maria Kalyva,Daniel J. DeAngelo,Ilene Galinsky,Martha Wadleigh,Eric S. Winer,Marlise R. Luskin,Richard Stone,Jacqueline S. Garcia,Gabriela S. Hobbs,Fernando D. Camargo,Fernando D. Camargo,Franziska Michor,Ann Mullally,Ann Mullally,Ann Mullally,Isidro Cortes-Ciriano,Sahand Hormoz,Sahand Hormoz +25 more
TL;DR: This article quantified the effect of the JAK2-V617F mutation on the self-renewal and differentiation dynamics of HSCs in treatment-naive individuals with myeloproliferative neoplasms and reconstructed lineage histories of individual hematopoietic stem cells using somatic mutation patterns.
Journal ArticleDOI
Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein.
Debra Van Egeren,Debra Van Egeren,Alexander Novokhodko,Madison Stoddard,Uyen Tran,Bruce R. Zetter,Michael S. Rogers,Bradley L. Pentelute,Jonathan M. Carlson,Mark S. Hixon,Diane Joseph-McCarthy,Arijit Chakravarty +11 more
TL;DR: In this article, the authors combined an analysis of the spike protein receptor-binding domain (RBD) structure-function with an evolutionary modeling framework to predict the frequency of immune escape before and after the widespread presence of nAbs due to vaccines, passive immunization or natural immunity.
Posted ContentDOI
Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein
Debra Van Egeren,Debra Van Egeren,Alexander Novokhodko,Madison Stoddard,Uyen Tran,Bruce R. Zetter,Bruce R. Zetter,Michael S. Rogers,Michael S. Rogers,Bradley L. Pentelute,Jonathan M. Carlson,Mark S. Hixon,Diane Joseph-McCarthy,Arijit Chakravarty +13 more
TL;DR: Evolutionary modeling suggests that SARS-CoV-2 mutants with one or two mildly deleterious mutations are expected to exist in high numbers due to neutral genetic variation, and likewise resistance to single or double antibody combinations will develop quickly under positive selection.
Journal ArticleDOI
Controlling long-term SARS-CoV-2 infections can slow viral evolution and reduce the risk of treatment failure.
Debra Van Egeren,Debra Van Egeren,Alexander Novokhodko,Madison Stoddard,Uyen Tran,Bruce R. Zetter,Bruce R. Zetter,Michael S. Rogers,Michael S. Rogers,Diane Joseph-McCarthy,Arijit Chakravarty +10 more
TL;DR: The authors used a stochastic evolutionary modeling framework to explore the emergence of fitter variants of SARS-CoV-2 during long-term infections and found that increased viral load and infection duration favor emergence of such variants.
Journal ArticleDOI
Individually optimal choices can be collectively disastrous in COVID-19 disease control.
Madison Stoddard,Debra Van Egeren,Debra Van Egeren,Kaitlyn E. Johnson,Smriti Rao,Josh Furgeson,Douglas E. White,Ryan P. Nolan,Natasha S. Hochberg,Natasha S. Hochberg,Arijit Chakravarty +10 more
TL;DR: The act of noncompliance with disease intervention measures creates a negative externality, rendering COVID-19 disease control ineffective in the short term and making complete suppression impossible in the long term, demonstrating the limits of free-market approaches to compliance with disease control measures during a pandemic.